These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29606522)

  • 21. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
    Vogelbaum MA; Hu C; Peereboom DM; Macdonald DR; Giannini C; Suh JH; Jenkins RB; Laack NN; Brachman DG; Shrieve DC; Souhami L; Mehta MP
    J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
    Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
    Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Going past the data for temozolomide.
    Villano JL; Letarte N; Bressler LR
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1113-5. PubMed ID: 22147076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
    DeAngelis LM
    J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
    [No Abstract]   [Full Text] [Related]  

  • 27. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 29. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemotherapy for brain tumors in adult patients].
    Weller M
    Nervenarzt; 2008 Feb; 79(2):231-41. PubMed ID: 18253773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
    Musat E; Roelofs E; Bar-Deroma R; Fenton P; Gulyban A; Collette L; Stupp R; Weber DC; Bernard Davis J; Aird E; Baumert BG
    Radiother Oncol; 2010 May; 95(2):218-24. PubMed ID: 20378192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
    Mikkelsen T; Doyle T; Anderson J; Margolis J; Paleologos N; Gutierrez J; Croteau D; Hasselbach L; Avedissian R; Schultz L
    J Neurooncol; 2009 Mar; 92(1):57-63. PubMed ID: 19011763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
    Broniscer A; Chintagumpala M; Fouladi M; Krasin MJ; Kocak M; Bowers DC; Iacono LC; Merchant TE; Stewart CF; Houghton PJ; Kun LE; Ledet D; Gajjar A
    J Neurooncol; 2006 Feb; 76(3):313-9. PubMed ID: 16200343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
    Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional conformal radiotherapy, temozolomide chemotherapy, and high-dose fractionated stereotactic boost in a protocol-driven, postoperative treatment schedule for high-grade gliomas.
    Pirtoli L; Rubino G; Marsili S; Oliveri G; Vannini M; Tini P; Miracco C; Santoni R
    Tumori; 2009; 95(3):329-37. PubMed ID: 19688972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
    Yang TM; Wang HC; Lin YJ; Lin WC; Lu CH; Chang WN; Chang HW; Ho JT
    Surg Neurol; 2008 Dec; 70 Suppl 1():S1:60-3. PubMed ID: 19061770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
    Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
    J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.